10-K: Anavex 10-K: EMA Rejects Alzheimer's Drug, Losses Mount

Anavex Life Sciences reports a negative trend vote from the EMA for its Alzheimer's drug blarcamesine, alongside increased net losses and decreased cash reserves for fiscal year 2025.

Summary

• Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases, including Alzheimer's, Parkinson's, schizophrenia, and Rett syndrome.
• The company's lead compound, ANAVEX2-73 (blarcamesine), showed positive results in its Phase 2b/3 Alzheimer's trial, meeting co-primary endpoints (ADAS-Cog13 and CDR-SB) with statistical significance (P < 0.025 for both).
• Blarcamesine slowed clinical progression in Alzheimer's by 36.3% overall, and by 38.5% (50mg group) and 34.6% (30mg group) versus placebo at 48 weeks.
• A long-term open-label extension study (ATTENTION-AD) for Alzheimer's demonstrated continued benefit for up to 192 weeks, with no new safety findings.
• On November 14, 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a negative trend vote on the Marketing Authorisation Application (MAA) for ANAVEX2-73 for Alzheimer's disease; the company plans to request a re-examination.
• ANAVEX2-73's Phase 2 trial for Parkinson's disease dementia showed clinically meaningful, dose-dependent, and statistically significant improvements in cognitive and motor impairment, with an open-label extension demonstrating longitudinal benefits.
• For Rett syndrome, ANAVEX2-73 received Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the FDA. Phase 2 (US) and Phase 3 (AVATAR) trials met primary and secondary efficacy and safety endpoints.
• The EXCELLENCE (pediatric Rett syndrome) trial showed a rapid onset of action with statistically significant improvements in RSBQ total score at 4 weeks (p=0.041), but the 12-week RSBQ total score (p=0.063) and the CGI-I co-primary endpoint were not met.
• ANAVEX3-71, for which the FDA granted Orphan Drug Designation for Frontotemporal Dementia (FTD), completed a Phase 1 trial demonstrating safety and tolerability.
• The Phase 2 ANAVEX3-71-SZ-001 clinical trial for schizophrenia met its primary safety endpoint and showed positive trends in objective EEG/ERP biomarkers and reduced glial fibrillary acidic protein (GFAP), a marker of neuroinflammation.
• The company reported a net loss of $46.4 million for fiscal year 2025, an increase from $43.0 million in fiscal year 2024, with an accumulated deficit of $382.4 million.
• Cash and cash equivalents decreased to $102.6 million at September 30, 2025, from $132.2 million at September 30, 2024.
• Operating expenses decreased slightly to $51.4 million in fiscal 2025 from $52.9 million in fiscal 2024, driven by a decrease in R&D expenses offset by an increase in general and administrative expenses.
• General and administrative expenses increased by $1.7 million, primarily due to legal fees related to ongoing class action and derivative lawsuits.
• The company entered into a Sales Agreement with TD Securities (USA) LLC in July 2025 to sell up to $150 million in common stock, raising $9.2 million in FY2025 with $140.4 million remaining.
• A 2023 Purchase Agreement with Lincoln Park Capital Fund, LLC for up to $150 million remains largely unused ($110.8 million), but requires a prospectus supplement to access funds.

Sentiment

Score: 3

Explanation: The negative trend vote from the EMA for the lead Alzheimer's drug is a significant setback, casting doubt on its commercialization prospects in a major market. This, combined with increasing net losses and declining cash reserves, indicates substantial financial and regulatory risks. While there are some positive clinical data points for other programs, the immediate outlook is highly unfavorable.

Positives

• ANAVEX2-73 Phase 2b/3 Alzheimer's trial met co-primary endpoints (ADAS-Cog13 and CDR-SB) with statistical significance (P < 0.025 for both).
• Blarcamesine significantly slowed clinical progression in Alzheimer's by 36.3% overall, and by 38.5% (50mg group) and 34.6% (30mg group) versus placebo at 48 weeks.
• The long-term open-label extension (ATTENTION-AD) for Alzheimer's demonstrated continued benefit for up to 192 weeks for ADAS-Cog13 (LS mean difference -3.83; P = 0.0165) and ADCS-ADL (LS mean difference +4.30, P = 0.0206).
• No new safety findings were observed with continued blarcamesine treatment over three years in the Alzheimer's program, confirming a good comparative safety profile.
• Delayed-start analysis in the Alzheimer's trial was significant, reflecting the importance of early treatment initiation.
• Precision medicine cohort in early Alzheimer's disease demonstrated cognitive stabilization, moving toward normal aging profiles across validated clinical scales.
• ANAVEX2-73 Phase 2 Parkinson's disease dementia trial showed clinically meaningful, dose-dependent, and statistically significant improvements in cognitive and motor impairment.
• ANAVEX2-73 for Rett Syndrome received Orphan Drug Designation, Rare Pediatric Disease (RPD) designation, and Fast Track designation from the FDA.
• ANAVEX2-73 Phase 2 (US) and Phase 3 (AVATAR, international) Rett syndrome trials met all primary and secondary efficacy and safety endpoints.
• The EXCELLENCE (pediatric Rett syndrome) trial demonstrated a rapid onset of action with statistically significant improvements in RSBQ total score at 4 weeks (p=0.041).
• High enrollment rate (over 91%) in the Rett syndrome Open Label Extension (OLE) and high requests (93%) for the Compassionate Use Program provide evidence of perceived patient benefit.
• ANAVEX3-71 Phase 1 clinical trial met its primary and secondary endpoints of safety, tolerability, and pharmacokinetics, with no serious adverse events or dose-limiting toxicities.
• ANAVEX3-71 Phase 2 schizophrenia trial successfully achieved its primary safety endpoint and showed positive trends in objective electroencephalography (EEG) and event-related potential (ERP) biomarkers, as well as reduced glial fibrillary acidic protein (GFAP), a marker of neuroinflammation.
• ANAVEX3-71 received Orphan Drug Designation for the treatment of Frontotemporal Dementia (FTD).
• The company holds a strong intellectual property portfolio with 30 issued U.S. patents and 17 pending U.S. patent applications.
• A shareholder class action lawsuit related to Rett syndrome disclosures was dismissed by the United States District Court for the Southern District of New York on June 18, 2025.
• The company maintained effective internal control over financial reporting as of September 30, 2025.

Negatives

• The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a negative trend vote on the Marketing Authorisation Application (MAA) for ANAVEX2-73 for the treatment of Alzheimer's disease.
• The functional co-primary endpoint, ADCS-ADL, in the ANAVEX2-73 Phase 2b/3 Alzheimer's trial, while trending positive, did not reach statistical significance at Week 48.
• The co-primary endpoint, Clinical Global Impression Improvement (CGI-I), in the EXCELLENCE (pediatric Rett syndrome) trial was not met.
• The RSBQ total score in the EXCELLENCE trial did not reach statistical significance at 12 weeks (p=0.063).
• The company has a history of losses and no revenue since its inception in 2004, with an accumulated deficit of approximately $382 million as of September 30, 2025.
• Net loss increased to $46.4 million for fiscal year 2025, compared to $43.0 million for fiscal year 2024.
• Cash and cash equivalents decreased to $102.6 million at September 30, 2025, from $132.2 million at September 30, 2024.
• Working capital decreased to $94.9 million at September 30, 2025, from $120.3 million at September 30, 2024.
• Net other income decreased significantly to $5.0 million in fiscal 2025 from $9.9 million in fiscal 2024, primarily due to lower interest income and a decrease in Australian R&D incentive income.
• General and administrative expenses increased by $2.8 million in fiscal 2025, largely due to a $1.7 million increase in legal fees related to legal/regulatory matters and class action lawsuits.
• The company expects to continue experiencing negative cash flows for the foreseeable future and cannot predict when, if ever, it might become profitable.
• The shareholder class action lawsuit, though dismissed, is currently under appeal, indicating ongoing legal uncertainty and potential future costs.
• Derivative lawsuits asserting breach of fiduciary duty and unjust enrichment claims are stayed pending the resolution of the class action appeal, representing continued legal exposure.

Risks

• The company's history of losses and no revenue raises a risk regarding its ability to continue as a going concern in the future.
• The company has a very limited relevant operating history upon which an evaluation of its future performance and prospects can be made.
• Research and development plans will require substantial additional future funding.
• The company may be unable to raise additional capital when needed, which would force it to delay, reduce, or eliminate its research and development activities.
• The marketing approval process for pharmaceutical products is lengthy, complex, highly regulated, and inherently unpredictable, which could lead to an inability to generate product revenue.
• If the company or any companion diagnostic collaborator is unable to timely develop and obtain regulatory approval for companion diagnostic tests for drug candidates, the commercial potential of drug candidates may not be realized.
• Regulatory authorities may not accept data from trials conducted outside the United States, requiring additional costly and time-consuming trials.
• Fast Track designation or breakthrough therapy designation may not actually lead to a faster FDA review and approval process.
• The company may be unable to maintain any benefits associated with orphan drug designation, including market exclusivity.
• Failure to demonstrate efficacy in non-clinical studies and clinical trials would materially adversely affect future business prospects.
• If a particular product candidate causes undesirable side effects, the company may be unable to receive regulatory approval or commercialize such product candidate.
• Treatment of neurodegenerative and central nervous system (CNS) disorders is a field that has seen very limited success in product development.
• The use of any of the company's products in clinical trials may expose it to liability claims.
• The company is highly dependent on its key personnel and may not be successful in attracting and retaining highly qualified personnel.
• Failure to obtain the support of qualified scientific collaborators could limit revenue, growth, and profitability.
• The company may not be able to develop, market, or generate sales of its products to the extent anticipated.
• Competitors may develop products and technologies faster or that are more effective or with a better profile, rendering the company's technologies undesirable or obsolete.
• Reliance on third parties (e.g., CROs, CMOs) may result in delays or failures in completing non-clinical testing or clinical trials.
• Failure to compete successfully with respect to partnering, licensing, mergers, acquisitions, joint venture, and other collaboration opportunities may limit the ability to research and develop potential drug compounds.
• The business could be affected by litigation, government investigations, and enforcement actions.
• Loss of access to Australian government research and development income tax incentive refunds could have a negative effect on future cash flows.
• The ability to use net operating loss carryforwards and tax credit carryforwards may be subject to limitation under Sections 382 and 383 of the Internal Revenue Code.
• Healthcare laws and regulations could expose the company to criminal sanctions, civil and administrative penalties, contractual damages, reputational harm, and diminished profits.
• Failure to obtain or maintain adequate coverage and reimbursement for product candidates, if approved, could limit the ability to market those products.
• Issuing additional shares of common stock will result in the dilution of existing stockholders and may cause the stock price to fall.
• The stock price has been volatile and may be volatile in the future, and common stock may become the target of a short squeeze.
• Inability to obtain and maintain sufficient intellectual property protection for product candidates could allow competitors to commercialize similar products.
• Intellectual property infringement claims may adversely affect development and commercialization efforts.
• The company may be subject to claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.
• Involvement in lawsuits to protect or enforce patents or other intellectual property could be expensive, time-consuming, and unsuccessful.
• Obtaining and maintaining patent protection depends on compliance with various requirements, and changes in patent law could impair the ability to protect product candidates.
• Failure to protect intellectual property rights or the confidentiality of trade secrets could harm the business.
• Material modifications in the methods of product candidate manufacturing may result in additional costs or delay.
• Operating internationally exposes the company to risks such as different standards of care, regulatory requirements, trade policies, economic instability, and foreign currency fluctuations.
• Changes in funding for the FDA, SEC, and other government agencies could hinder their ability to perform normal functions, impacting the business.

Future Outlook

The company expects research and development expenditures to increase as it continues to advance its pipeline compounds. It plans to request a re-examination of the EMA's negative trend vote for blarcamesine in Alzheimer's disease and anticipates conducting further clinical trials for ANAVEX2-73 in Parkinson's disease dementia. ANAVEX3-71 is intended to advance into a biomarker-driven clinical development dementia program for schizophrenia, FTD, and Alzheimer's disease. Management expects continued negative cash flows for the foreseeable future and cannot predict when profitability might be achieved, necessitating additional funding. New legislation (OBBBA) effective fiscal 2026 will provide more tax-favorable treatment for domestic R&D expenditures.

Management Comments

• Management believes that the current working capital position will be sufficient to meet the Company’s working capital requirements beyond the next 12 months after the date that these consolidated financial statements are issued.
• We expect to see our research and development expenditures increase from current levels as we continue to advance our pipeline compounds.
• We expect to continue to receive support from the Australian government for future clinical trials which we plan to conduct, in part, within Australia.
• The Company is committed to maintaining transparency in its executive compensation practices and to making equity awards in a manner that is not influenced by the timing of the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.

Industry Context

The company operates in the highly competitive biotechnology and pharmaceutical industries, characterized by rapid technological advancements and significant unmet medical needs in CNS diseases. The development of neurodegenerative and CNS therapies presents unique challenges, including an imperfect understanding of biology and the blood-brain barrier. The Alzheimer's market is substantial, with 7.2 million Americans aged 65+ living with dementia in 2025, and new cases projected to double by 2050, highlighting an urgent need for disease-modifying treatments. The Parkinson's disease market is expected to reach $11.5 billion by 2029, and schizophrenia affects nearly 24 million people worldwide, with many patients not responding adequately to current treatments. The company's focus on SIGMAR1 activation represents a differentiated approach in these challenging therapeutic areas. The regulatory environment, particularly with the FDA and EMA, is increasingly stringent regarding product safety and risk/benefit profiles. Recent U.S. legislation, such as the Inflation Reduction Act and the One Big Beautiful Bill Act, indicates a trend toward increased scrutiny of drug pricing and changes in R&D tax treatment, which will impact the pharmaceutical industry.

Comparison to Industry Standards

• The company's ANAVEX2-73 Alzheimer's trial demonstrated a mean change from baseline ADAS-Cog13 total score difference of 2.68 points (p < 0.0001) compared to an externally matched ADNI control group at 48 weeks, which is considered a clinically meaningful improvement (greater than 2 points, per Muir RT et al., Alzheimers Dement. 2024).
• Cognitive outcomes in the oral blarcamesine 30 mg precision medicine cohort showed a 48-week change from baseline of 0.853 for ADAS-Cog13, compared to a typical annual decline of ~1 point in prodromal aging adults, and a CDR-SB change of 0.465, aligning with the 0-0.5 point annual range seen in prodromal aging. This suggests a potential to stabilize cognitive decline in early Alzheimer's patients, which could be competitive in a field with limited disease-modifying options.
• The company's approach of SIGMAR1 activation is presented as a novel, disease-modifying strategy in neurodegenerative and neurodevelopmental diseases, differentiating it from many existing symptomatic treatments in the CNS space, which has historically seen limited success in product development.
• While the company faces significant competition from larger, more established pharmaceutical and biotechnology companies with greater resources, its focus on precision medicine and specific biomarker identification aims to target patient populations more likely to respond, potentially offering a competitive advantage in efficacy for those subsets.

Corporate Governance

Legal Proceedings

• On March 13, 2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York, alleging violations of the Securities and Exchange Act of 1934 related to disclosures and statements made about certain clinical trials for ANAVEX2-73 related to Rett syndrome. This lawsuit was dismissed on June 18, 2025, but the plaintiff filed a notice of appeal on July 17, 2025, with briefing concluded on October 30, 2025.
• On May 8, 2024, a similar complaint was filed by Kenneth Downing, a purported shareholder, in the same court, which was voluntarily dismissed after the company filed a motion to dismiss.
• On or about May 13, 2024, a derivative lawsuit was filed against the company (as nominal defendant), an officer, and members of the Board of Directors in the U.S. District Court for the District of Nevada, asserting common law claims (including breach of fiduciary duty) and a violation of Section 14(a) of the Securities Exchange Act, based on similar allegations as the class action. This lawsuit was stayed on January 22, 2025, until the motion to dismiss in the Initial Action is decided, and the stay has been extended through the appeal.
• On February 14, 2025, another derivative lawsuit asserting state law breach of fiduciary duty and unjust enrichment claims based upon similar allegations was filed against the company (as nominal defendant), an officer, and Board members in the Supreme Court for the State of New York, County of New York. This lawsuit was stayed on August 18, 2025, until the appeal in the Initial Action is resolved.
• No amount has been recorded in the consolidated financial statements for any loss contingencies associated with these lawsuits, as the company believes it is not probable that any loss will occur.

Related Party Transactions

• During the fiscal year ended September 30, 2025, the brother of the CEO provided legal services to the company, for which the company paid $88,541 and issued options to purchase 50,000 shares of common stock with a grant date fair value of $308,200. The options vest in four equal tranches based on performance milestones.

Stakeholder Impact

• **Shareholders**: Face significant uncertainty due to the EMA's negative trend vote for a key drug, ongoing legal proceedings, and the company's history of losses and declining cash. Potential for further dilution from future capital raises and stock price volatility remains high.
• **Employees**: The company's ability to attract and retain highly qualified personnel is critical, especially given the competitive industry. Compensation programs, including equity awards and a clawback policy, aim to align incentives and ensure accountability.
• **Customers (future)**: The success or failure of drug candidates directly impacts the availability of new treatments for severe CNS diseases. Regulatory approvals, safety profiles, and pricing will determine access and adoption.
• **Creditors**: The company's going concern risk, history of negative cash flows, and reliance on future financing could impact its creditworthiness and ability to meet obligations.
• **Suppliers/Partners**: Reliance on third-party contract research and manufacturing organizations means their performance and compliance are crucial to the company's development timelines and success. Any failures or delays from these partners could adversely affect the company's programs.

Next Steps

• Request a re-examination of the CHMP's negative opinion on the Marketing Authorisation Application (MAA) for blarcamesine for Alzheimer's disease.
• Conduct further clinical trials of ANAVEX2-73 in Parkinson's disease dementia after submitting results to regulatory authorities.
• Advance ANAVEX3-71 into a biomarker-driven clinical development dementia program for the treatment of schizophrenia, Frontotemporal Dementia (FTD), and Alzheimer's disease.
• Continue to seek additional funding through equity or convertible debt financing to support operations and pipeline advancement.
• Continue to receive support from the Australian government for future clinical trials planned to be conducted in Australia.
• Assess the impact of ASU No. 2023-09 (Income Taxes: Improvements to Income Tax Disclosures) on its disclosures for the fiscal year ending September 30, 2026.
• Assess the impact of ASU No. 2024-03 (Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures) on its disclosures for fiscal years beginning after December 15, 2026.

Key Dates

Recommendation

The negative trend vote from the EMA for blarcamesine in Alzheimer's disease is a critical setback for a lead candidate, significantly diminishing its near-term commercial prospects in a major market. This regulatory blow, combined with the company's persistent net losses, declining cash reserves, and ongoing legal challenges, creates a highly unfavorable risk-reward profile. While there are some positive clinical data points for other programs, the overall financial health and immediate regulatory outlook warrant a 'sell' recommendation to mitigate further downside risk for investors.

Keywords

Anavex Life Sciences, AVXL, Biopharmaceutical, Clinical Stage, CNS Diseases, Alzheimer's Disease, Parkinson's Disease, Rett Syndrome, Schizophrenia, ANAVEX2-73, Blarcamesine, ANAVEX3-71, SIGMAR1, Orphan Drug, Fast Track, EMA, FDA, Clinical Trials, Neurodegenerative, Neurodevelopmental, Financial Results, 10-K, SEC Filing, Drug Development, Biotech, Pharmaceutical, Intellectual Property, Capital Raise